Intercept Pharmaceuticals Inc
ICPT
19.00USDÂ DelayedWatchlist
Market Summary
USD19.00
DelayedICPT Stock Price
View Fullscreen
ICPT RSI Chart
ICPT Valuation
ICPT Price/Sales (Trailing)
ICPT Profitability
ICPT Fundamentals
ICPT Revenue
ICPT Earnings
Price Action
Last 7 days
0.1%
Last 30 days
1.4%
Last 90 days
81.3%
Trailing 12 Months
19.1%
How does ICPT drawdown profile look like?
ICPT Financial Health
ICPT Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 294.5M | 306.5M | 317.7M | 0 |
| 2022 | 262.6M | 266.2M | 277.1M | 285.7M |
| 2021 | 297.3M | 288.3M | 275.4M | 260.8M |
| 2020 | 272.4M | 283.4M | 300.9M | 312.7M |
| 2019 | 196.1M | 218.8M | 233.8M | 252.0M |
| 2018 | 145.9M | 158.6M | 164.2M | 179.8M |
| 2017 | 45.6M | 70.9M | 107.1M | 131.0M |
| 2016 | 1.8M | 6.9M | 11.6M | 25.0M |
| 2015 | 2.8M | 2.8M | 2.8M | 2.8M |
| 2014 | 1.6M | 1.7M | 1.7M | 1.7M |
| 2013 | 2.1M | 1.7M | 1.6M | 1.6M |
| 2012 | 2.6M | 2.9M | 2.8M | 2.4M |
| 2011 | 0 | 0 | 0 | 1.8M |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for ICPT
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Nov 08, 2023 | miller-rich nancy | back to issuer | -154,109 | 19.00 | -8,111 | - |
| Nov 08, 2023 | benatti luca | back to issuer | -154,109 | 19.00 | -8,111 | - |
| Nov 08, 2023 | santini gino | back to issuer | -154,109 | 19.00 | -8,111 | - |
| Nov 08, 2023 | ford david a | back to issuer | -406,600 | 19.00 | -21,400 | chief human resources officer |
| Nov 08, 2023 | miller-rich nancy | sold | -423,776 | 19.00 | -22,304 | - |
| Nov 08, 2023 | akkaraju srinivas | sold | -719,853 | 19.00 | -37,887 | - |
| Nov 08, 2023 | saik andrew | back to issuer | -859,636 | 19.00 | -45,244 | evp & chief financial officer |
| Nov 08, 2023 | venezia rocco | sold | -204,858 | 19.00 | -10,782 | chief accounting officer |
| Nov 08, 2023 | akkaraju srinivas | back to issuer | -154,109 | 19.00 | -8,111 | - |
| Nov 08, 2023 | venezia rocco | back to issuer | -278,711 | 19.00 | -14,669 | chief accounting officer |
Which funds bought or sold ICPT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Dec 06, 2023 | CITIGROUP INC | reduced | -87.65 | -10,186,200 | 2,658,900 | -% |
| Nov 29, 2023 | Carmignac Gestion | new | - | 1,580,920 | 1,580,920 | 0.03% |
| Nov 24, 2023 | DEUTSCHE BANK AG\ | reduced | -34.42 | 24,718 | 273,557 | -% |
| Nov 22, 2023 | Graham Capital Management, L.P. | sold off | -100 | -170,058 | - | -% |
| Nov 21, 2023 | Alpine Global Management, LLC | new | - | 1,656,000 | 1,656,000 | 0.21% |
| Nov 21, 2023 | COMERICA BANK | new | - | 358 | 358 | -% |
| Nov 17, 2023 | JACOBS LEVY EQUITY MANAGEMENT, INC | sold off | -100 | -9,531,520 | - | -% |
| Nov 15, 2023 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | added | 44.03 | 162,754 | 277,822 | -% |
| Nov 15, 2023 | Tudor Investment Corp Et Al | new | - | 463,500 | 463,500 | -% |
| Nov 15, 2023 | PIN OAK INVESTMENT ADVISORS INC | unchanged | - | 1,000 | 3,000 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Intercept Pharmaceuticals Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Oct 10, 2023 | vanguard group inc | 4.95% | 2,071,222 | SC 13G/A | |
| Jul 10, 2023 | vanguard group inc | 11.26% | 4,693,807 | SC 13G/A | |
| Jul 07, 2023 | blackrock inc. | 10.5% | 4,396,970 | SC 13G/A | |
| Feb 14, 2023 | point72 asset management, l.p. | 0.4% | 166,300 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.78% | 3,637,935 | SC 13G/A | |
| Feb 02, 2023 | state street corp | 7.67% | 3,175,925 | SC 13G/A | |
| Jan 31, 2023 | blackrock inc. | 7.4% | 3,084,833 | SC 13G/A | |
| Jan 13, 2023 | millennium management llc | 2.4% | 976,706 | SC 13G/A | |
| Sep 02, 2022 | genextra s.p.a. | 13.4% | 4e+06 | SC 13G/A | |
| Aug 18, 2022 | millennium management llc | 5.1% | 1,524,316 | SC 13G |
Recent SEC filings of Intercept Pharmaceuticals Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Nov 20, 2023 | 15-12G | 15-12G | |
| Nov 14, 2023 | EFFECT | EFFECT | |
| Nov 14, 2023 | EFFECT | EFFECT | |
| Nov 14, 2023 | EFFECT | EFFECT | |
| Nov 13, 2023 | 4 | Insider Trading | |
| Nov 13, 2023 | 4 | Insider Trading | |
| Nov 13, 2023 | 4 | Insider Trading | |
| Nov 13, 2023 | 4 | Insider Trading | |
| Nov 13, 2023 | 4 | Insider Trading | |
| Nov 13, 2023 | 4 | Insider Trading |
ICPT Fair Value
Loading...
Peers (Alternatives to Intercept Pharmaceuticals Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 31.5B | - | 6.13% | 411799.31% | -3.7K | 218.4K | - | -102.45% |
MRNA | 30.6B | 10.7B | 12.59% | -56.51% | -8.83 | 2.87 | -53.67% | -129.46% |
ALNY | 21.3B | 1.7B | 0.38% | -28.56% | -41.84 | 12.38 | 79.37% | 56.87% |
BMRN | 17.5B | 2.3B | 8.71% | -10.95% | 119.09 | 7.58 | 15.05% | 75.21% |
INCY | 12.3B | 3.6B | 1.18% | -34.97% | 28.84 | 3.4 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 7.4B | 272.9M | 33.62% | 24.68% | -12.26 | 27.23 | 141.38% | 4.43% |
BBIO | 5.7B | - | 10.65% | 240.88% | -9.69 | 48.33 | 54.84% | -12.96% |
ACAD | 3.4B | 631.9M | -9.53% | 43.40% | -23.12 | 5.44 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 14.00% | -9.85% | -16.45 | 14.86 | - | -26.24% |
ARWR | 2.6B | 240.7M | -11.63% | -24.14% | -12.52 | 10.67 | -1.03% | -16.59% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 12.92% | -15.71% | 24.33 | 4.33 | 81.69% | -7.29% |
NVAX | 661.3M | 1.0B | -18.09% | -67.84% | -1.2 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | - | -79.35% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 37.6M | - | 385.71% | 119.35% | -0.58 | - | - | -29.23% |
CRBP | 23.7M | - | 40.31% | 4064.72% | -0.5 | - | - | -13.74% |
Intercept Pharmaceuticals Inc News
Latest updates
Financials for Intercept Pharmaceuticals Inc
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | 6.1% | 89.00 | 84.00 | 68.00 | 77.00 | 78.00 | 72.00 | 59.00 | 69.00 | 67.00 | 68.00 | 57.00 | 83.00 | 80.00 | 77.00 | 73.00 | 72.00 | 62.00 | 66.00 | 52.00 | 53.00 | 47.00 |
| Cost Of Revenue | 6.5% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | -2.20 | 2.00 | 2.00 | 1.00 | 2.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Costs and Expenses | 2.8% | 93.00 | 91.00 | 100 | 95.00 | 88.00 | 85.00 | 86.00 | 90.00 | 86.00 | 82.00 | 111 | 44.00 | 135 | 129 | 156 | 161 | 137 | 130 | 136 | 135 | 105 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 136 | 135 | 105 |
| S&GA Expenses | -14.8% | 45.00 | 53.00 | 58.00 | 55.00 | 43.00 | 40.00 | 38.00 | 40.00 | 41.00 | 44.00 | 59.00 | -2.03 | 71.00 | 93.00 | 99.00 | 94.00 | 77.00 | 70.00 | 77.00 | 71.00 | 57.00 |
| R&D Expenses | 11.3% | 42.00 | 37.00 | 42.00 | 40.00 | 44.00 | 45.00 | 48.00 | 50.00 | 45.00 | 38.00 | 51.00 | 49.00 | 49.00 | 34.00 | 57.00 | 65.00 | 60.00 | 60.00 | 58.00 | 63.00 | 48.00 |
| Interest Expenses | -35.9% | 2.00 | 3.00 | 3.00 | 3.00 | 5.00 | 7.00 | 7.00 | 15.00 | 14.00 | 13.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 | 10.00 | 8.00 | 8.00 | 8.00 |
| Net Income | 52.4% | -2.79 | -5.86 | -32.13 | -20.82 | 267 | -7.53 | -17.28 | -36.28 | -3.63 | -11.09 | -40.42 | -52.15 | -66.47 | -63.28 | -92.98 | -98.16 | -84.83 | -71.42 | -90.27 | -88.00 | -64.45 |
| Net Income Margin | -128.5% | -0.19* | 0.68* | 0.70* | 0.78* | 0.67* | -0.15* | -0.18* | -0.25* | -0.30* | -0.50* | -0.69* | -0.88* | -1.07* | -1.20* | -1.28* | -1.37* | -1.43* | -1.44* | -1.62* | -1.72* | -2.02* |
| Free Cashflow | - | 17.00 | - | -51.30 | -4.51 | -16.92 | 14.00 | -20.13 | 4.00 | 4.00 | 5.00 | -55.03 | -17.88 | -41.81 | -15.07 | -99.16 | -60.58 | -46.77 | -46.24 | -84.16 | -52.93 | -51.58 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | -18.9% | 393 | 485 | 504 | 554 | 559 | 499 | 503 | 527 | 523 | 523 | 520 | 580 | 591 | 637 | 662 | 755 | 802 | 853 | 438 | 509 | 557 |
| Current Assets | -18.5% | 383 | 471 | 490 | 540 | 545 | 487 | 477 | 508 | 496 | 493 | 488 | 546 | 561 | 607 | 628 | 721 | 769 | 819 | 403 | 482 | 529 |
| Cash Equivalents | -24.6% | 103 | 136 | 61.00 | 51.00 | 113 | 58.00 | 48.00 | 85.00 | 68.00 | 146 | 93.00 | 58.00 | 45.00 | 51.00 | 41.00 | 70.00 | 63.00 | 94.00 | 55.00 | 43.00 | 59.00 |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.00 | 7.00 | 7.00 |
| Net PPE | -9.3% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 3.00 | 3.00 | 4.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 6.00 | 7.00 | 7.00 | 10.00 | 11.00 |
| Liabilities | -23.0% | 321 | 417 | 437 | 461 | 452 | 868 | 875 | 711 | 679 | 726 | 720 | 747 | 722 | 716 | 697 | 703 | 671 | 678 | 493 | 490 | 461 |
| Current Liabilities | -51.4% | 91.00 | 187 | 207 | 230 | 222 | 151 | 151 | 168 | 144 | 145 | 146 | 179 | 163 | 164 | 150 | 162 | 140 | 125 | 108 | 114 | 88.00 |
| LT Debt, Non Current | 0.1% | 224 | 224 | 223 | 223 | 223 | 714 | 717 | 540 | 530 | 576 | 568 | 561 | 553 | 546 | 539 | 532 | 525 | 545 | 375 | 371 | 367 |
| Shareholder's Equity | 6.4% | 72.00 | 68.00 | 67.00 | 93.00 | 108 | -369 | - | -183 | - | - | - | - | - | - | - | 52.00 | 131 | 175 | - | 19.00 | 96.00 |
| Retained Earnings | -0.1% | -2,177 | -2,174 | -2,169 | -2,136 | -2,116 | -2,383 | -2,375 | -2,489 | -2,453 | -2,449 | -2,438 | -2,398 | -2,346 | -2,279 | -2,216 | -2,123 | -2,025 | -1,940 | -1,869 | -1,778 | -1,690 |
| Additional Paid-In Capital | 0.3% | 2,257 | 2,250 | 2,244 | 2,238 | 2,232 | 2,016 | 2,008 | 2,309 | 2,300 | 2,249 | 2,241 | 2,234 | 2,218 | 2,202 | 2,186 | 2,176 | 2,157 | 2,116 | 1,815 | 1,800 | 1,788 |
| Shares Outstanding | 0.1% | 42.00 | 42.00 | 42.00 | 42.00 | 41.00 | 30.00 | 30.00 | 30.00 | 32.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 31.00 | 31.00 | 30.00 | 28.00 | 30.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | 171.6% | 16,686 | -23,302 | -51,597 | -4,806 | -16,588 | 14,738 | -20,124 | 5,175 | 3,562 | 4,847 | -54,650 | -17,813 | -40,478 | -14,842 | -98,731 | -60,484 | -46,756 | -45,948 | -83,425 | -52,812 | -51,581 |
| Share Based Compensation | 6.2% | 6,653 | 6,262 | 5,864 | 5,231 | 5,788 | 5,489 | 5,381 | 7,151 | 7,188 | 5,274 | 8,419 | 4,805 | 15,825 | 16,083 | 12,473 | 13,173 | 13,130 | 14,782 | 14,897 | 11,499 | 11,994 |
| Cashflow From Investing | -38.3% | 59,774 | 96,946 | 59,323 | -54,935 | 331,582 | -578 | -14,220 | 15,328 | -84,257 | 48,315 | 91,340 | 29,844 | 35,092 | 26,064 | 71,817 | 65,888 | 16,475 | -365,818 | 94,467 | 36,929 | 31,542 |
| Cashflow From Financing | -255711.6% | -109,999 | -43.00 | -254 | -5,672 | -257,402 | -3,924 | -318 | -965 | 3,390 | -224 | -1,083 | -156 | -226 | 442 | -753 | 5,880 | 892 | 450,595 | 152 | 440 | 1,262 |
ICPT Income Statement
2023-09-30Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Condensed Consolidated Statements of Operations | ||||
| Revenue | $ 88,789 | $ 77,588 | $ 240,465 | $ 208,491 |
| Revenue, Product and Service [Extensible Enumeration] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember |
| Operating expenses: | ||||
| Cost of sales | $ 197 | $ 424 | $ 604 | $ 956 |
| Selling, general and administrative | 45,438 | 43,274 | 156,441 | 121,013 |
| Research and development | 41,513 | 44,034 | 120,530 | 136,753 |
| Restructuring | 6,260 | 6,260 | ||
| Total operating expenses | 93,408 | 87,732 | 283,835 | 258,722 |
| Operating loss | (4,619) | (10,144) | (43,370) | (50,231) |
| Other income (expense): | ||||
| Interest expense | (1,802) | (5,237) | (7,423) | (18,579) |
| Loss on extinguishment of debt | (91,759) | (91,739) | ||
| Other income, net | 3,661 | 3,053 | 10,326 | 2,691 |
| Total other income (expense), net | 1,859 | (93,943) | 2,903 | (107,627) |
| Loss from continuing operations | (2,760) | (104,087) | (40,467) | (157,858) |
| (Loss) income from discontinued operations, net of income taxes | (30) | 371,540 | (320) | 400,499 |
| Net (loss) income | $ (2,790) | $ 267,453 | $ (40,787) | $ 242,641 |
| Net income (loss) per common and potential common share (basic and diluted): | ||||
| Net loss from continuing operations, Basic (in dollars per share) | $ (0.07) | $ (3.04) | $ (0.97) | $ (5.05) |
| Net loss from continuing operations, Diluted (in dollars per share) | (0.07) | (3.04) | (0.97) | (5.05) |
| Net (loss) income from discontinued operations, Basic (in dollars per share) | 0.00 | 10.83 | (0.01) | 12.81 |
| Net (loss) income from discontinued operations, Diluted (in dollars per share) | 0.00 | 10.83 | (0.01) | 12.81 |
| Net (loss) income, Basic (in dollars per share) | (0.07) | 7.80 | (0.98) | 7.76 |
| Net (loss) income, Diluted (in dollars per share) | $ (0.07) | $ 7.80 | $ (0.98) | $ 7.76 |
| Weighted average common and potential common shares outstanding: | ||||
| Basic (in shares) | 41,792 | 34,293 | 41,731 | 31,262 |
| Diluted (in shares) | 41,792 | 34,293 | 41,731 | 31,262 |
ICPT Balance Sheet
2023-09-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 102,736 | $ 50,517 |
| Restricted cash | 920 | 5,343 |
| Investment debt securities, available-for-sale | 219,978 | 435,049 |
| Accounts receivable, net of allowance for credit losses of $65 and $54, respectively | 32,479 | 26,862 |
| Prepaid expenses and other current assets | 27,332 | 22,356 |
| Total current assets | 383,445 | 540,127 |
| Fixed assets, net | 822 | 987 |
| Inventory | 2,649 | 6,462 |
| Security deposits | 1,275 | 1,013 |
| Other assets | 4,971 | 5,122 |
| Total assets | 393,162 | 553,711 |
| Current liabilities: | ||
| Accounts payable, accrued expenses and other liabilities | 89,494 | 116,977 |
| Short-term interest payable | 1,351 | 3,531 |
| Current portion of long-term debt | 109,569 | |
| Total current liabilities | 90,845 | 230,077 |
| Long-term liabilities: | ||
| Long-term debt | 223,856 | 223,104 |
| Long-term other liabilities | 6,616 | 7,453 |
| Total liabilities | 321,317 | 460,634 |
| Commitments and contingencies (Note 15) | ||
| Stockholders' equity: | ||
| Common stock par value $0.001 per share; 90,000,000 shares authorized; 41,811,686 and 41,523,337 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | 42 | 42 |
| Additional paid-in capital | 2,256,681 | 2,238,179 |
| Accumulated other comprehensive loss, net | (7,203) | (8,256) |
| Accumulated deficit | (2,177,675) | (2,136,888) |
| Total stockholders' equity | 71,845 | 93,077 |
| Total liabilities and stockholders' equity | $ 393,162 | $ 553,711 |
| Â CEO | Mr. Jerome B. Durso |
|---|---|
| Â WEBSITE | www.interceptpharma.com |
| Â EMPLOYEES | 341 |